BMS Launches Cardiac Myosin Inhibitor Camzyos in China for Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin...
Boston Scientific Reports 19.5% YOY Increase in Q3 Net Sales, Driven by New Product Launches and Market Expansion
Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced...
Hengrui Pharmaceuticals Considers HKEX Secondary Listing Amid Financing Challenges in Mainland China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, is reportedly planning...
Everest Medicines’ Velsipity Approved for Use in Select Hospitals in China’s Greater Bay Area
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval...
Daiichi Sankyo’s Pexidartinib Poised for Priority Review in China for TGCT Treatment
The official website of the Center for Drug Evaluation (CDE) under China’s National Medical Products...
AbbVie and Gedeon Richter Expand Partnership to Develop Novel Neuropsychiatric Targets
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing...
Asieris Pharmaceuticals Gets FDA Green Light for USP1 Inhibitor APL-2302 in Advanced Solid Tumors
Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has announced that it...
Henlius Biotech Commences Global Phase III Trial for Serplulimab in First-Line Metastatic Colorectal Cancer
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Dual-Target Therapy in Systemic Lupus Erythematosus
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a Chinese biopharmaceutical company, has announced the first...
China’s NHSA Sets October Dates for National Reimbursement Drug List Negotiations and Price Bidding
The National Healthcare Security Administration (NHSA) has announced that the one-site negotiation and price bidding...
Sanofi’s Dupixent Demonstrates Positive Results in Phase III Study for Chronic Urticaria
Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced the presentation of new data from...
3SBio Secures Exclusive Rights to Commercialize Haihe’s Paclitaxel Oral Solution in China and Hong Kong
Shanghai Haihe Pharmaceutical Co., Ltd and 3SBio Inc. (HKG: 1530), two Chinese pharmaceutical companies, have...
China’s NMPA and Denmark’s Medicines Agency Commit to Enhanced Regulatory Cooperation
The National Medical Products Administration (NMPA) of China and the Danish Medicines Agency have signed...
NucMito and Amoytop Biotech Seal Deal for Development and Commercialization of NASH Drug Candidate in Greater China
NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing...
HELP Therapeutics Receives FDA Clearance for Phase I Clinical Trial of HiCM-188 Cell Therapy
HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company headquartered in Nanjing, has announced that...
Merck Acquires Modifi Biosciences to Target DNA Repair Defects in Cancer Therapies
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has bolstered...
Eli Lilly’s Alzheimer’s Drug Kisunla Secures Marketing Approval in Great Britain
Eli Lilly & Co. (NYSE: LLY) has announced that it has received marketing approval in...
Sino Medical Sciences Technology Secures Marketing Approval for Coronary Balloon Dilation Catheter in Morocco
Sino Medical Sciences Technology Inc., (SHA: 688108) a China-based medical device company, has announced that...
Gan & Lee Pharmaceuticals Initiates Phase I Clinical Trial for Biosimilar Secukinumab
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the commencement of...
Lundbeck’s Vyepti Migraine Treatment Available at Sun Yat-sen Memorial Hospital Through Greater Bay Area Policy
Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF),...